GLG News by Pancreatic Cancer Oncologists in the U.S.
Articles with lock require a subscription to GLG News |
Request a free trial
November 26, 2008It's always what's relative and seldom absolute
Analysis of: Scientists recommend 'black box' for Avastin | www.fiercepharma.com
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
Satistics are usually used to reveal dramatic differences Patients often misinterpret relative differences for absolute ones patients are willing to do a lot more to get any benefit in cancer outcome
November 19, 2008The rash and EGFR response can be helpful
Analysis of: Merck KGaA: Overall Survival in First-Line NSCLC Reaches 15 Months | www.pipelinereview.com
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
Many studies support EGFR response correlates with rash Many attempts to actually increase the incidence of rash Most patients will use the EGFR treatments despite the rash
November 13, 2008When being selective, targeted therapy will work
Analysis of: Tarceva successful as maintenance therapy | www.fiercebiotech.com
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
Saturn trial attempted to focus on EGFR reative patients Saturn was positive as a maintenance therapy, while concurrent was not
October 28, 2008The TKI's are building on their success
Analysis of: Phase II Trial of Sorafenib in Advanced Thyroid Cancer | jco.ascopubs.org
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
TKI's have been establihed in a small number of refractory solid cancers With slow migration to other venues, we are seeing new applications
October 28, 2008Vaccine for prostate cancer fails
Analysis of: Cell Genesys Announces Termination of VITAL-1 Phase 3 Trial of GVAX Immunotherapy for Prostate Cancer | pharmalive.com
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
Recent Cell Genesys vaccine trial for prostate cancer fails
The trial not only shows lack of efficacy, but possible harm from the vaccine arm of the trial
October 27, 2008Hitting the target may reduce the use of targeted cancer drugs or not
Analysis of: Targeting EGFR in Colorectal Cancer | content.nejm.org
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
We are facing an ever increasing expense of treating cancver
The so called targeted drugs are the big price items
The recent discovery of theses drugs have sometimes been out of order with understanding their activity
October 24, 2008The vaccine approach to cancer has yet to succeed
Analysis of: Cell Genesys Announces Termination of VITAL-1 Phase 3 Trial of GVAX Immunotherapy for Prostate Cancer | pharmalive.com
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
Be cautious of vaccine approaches to cancer No cancer has had success with the use of vaccine therapy We are far from figuring out the reason for failure of vaccines to treat cancer
October 20, 2008We must hit the cancer target by genetics or whatever technique
Analysis of: Genetic Research May Help Pick Patients' Best Cancer Drugs | online.wsj.com
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
Targeted therapy for cancer is the new trend
Targeted therapy will allow the use of more expensive drugs to be more practical
We need to focus on hitting a target more than ever
October 20, 2008Government Run Cancer care
Analysis of: Roche Cuts Price of Cancer Drug | online.wsj.com
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
There has been distubing trends in nationalized health care in regrds to cancer care
Recently the UK made an absolutely shocking decision on renal cancer therapy, as it has in other cancers in the past
Hopefully through advances in predicting cancer therapy outcomes via microarray etc. we can...
October 9, 2008Beta trial negative, but is it truely blinded
Analysis of: Genentech Set Back by Cancer-Drug Study | online.wsj.com
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
Beta trial implies that Avastin adds to the effectiveness of the other Genentech drug, Tarceva There is an attempt to change treatment gudelines in second line non small treatment
Page : 1 2 3 4 5 6 7 8 9 10 Next1 to 10 of 93
More GLG News in
Healthcare
Most Popular:
Source Article | Expert Analyses
Why the doctor can't see you now
seattlepi.nwsource.com
Johnson & Johnson buys medical device maker
www.nytimes.com
Potassium loss from blood pressure drugs may explain higher risk of adult diabetes
www.fiercebiotech.com
McKesson Agrees To Settlement In Pricing Suits
online.wsj.com
Use of Antipsychotics in Children Poses Risks of Adverse Effects
November 26, 2008
Avastin and clots? News to me. Black box warning? Why?
November 24, 2008
Off Label Use Can Be Prevented
November 24, 2008
Gardasil will most certainly be approved for boys
November 24, 2008
Medivations's (MDVN) Dimebon - We've Seen This Movie Before
November 24, 2008